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In a retrospective survey of patients hospitalized in the University Hospital of Basel, Switzer-
land, the course and outcome of 281 cases of true bacteremia due to Staphylococcus aureus over a
7-year period were analyzed. The main purpose was to evaluate different case definitions. In 78%
of cases the source of bacteremia was obvious; vascular access sites (27%) and wounds (10%) were
the most common sources. Metastasizing foci were more common in cases of primary vs. second-
ary bacteremia (P < .001). The incidence of endocarditis was higher in cases in which no portal of
entry was defined (P < .03). The overall mortality rate was high at 34% partly because of inappro-
priate initial antibiotic therapy. With the introduction of an infectious disease service at the
hospital, the fraction of misjudged results of blood culture diminished 2.5-fold. Among the
differently defined cases, the mortality rate was significantly higher for cases of complicated vs.
uncomplicated bacteremia (P < .01), for cases of primary vs. secondary bacteremia (P = .05), and
for patients with endocarditis or other secondary foci (P < .001). Since only one methicillin-resis-
tant strain was isolated, multiresistant staphylococci were not a problem in the hospital. Differ-
ent case definitions allowed the detection of patients at increased risk for complications and
death. In the treatment of sepsis with no evident focus, initial antimicrobial therapy should
include the use of agents with antistaphylococcal activity.
Since the introduction of antimicrobial agents, consider-
able changes have taken place regarding the pattern of bacte-
rial species causing bacteremia. Streptococcus pneumoniae
and other streptococci have largely been replaced in this role
by staphylococci and gram-negative rods [1-12]. During a
7-year period, 2,746 episodes of bacteremia associated with
positive blood cultures were diagnosed at the University Hos-
pital in Basel, Switzerland. In 373 episodes (13.6%) Staphylo-
coccus aureus was isolated. The purpose of this retrospective
study was to analyze the course and outcome of 281 episodes
of true bacteremia due to S. aureus, with special emphasis on
acquisition, clinical severity, nature of infection, and pri-
mary focus.
Patients, Definitions, and Methods
The University Hospital of Basel is a 1,000-bed acute care
facility. From 1 January 1980 through 31 December 1986
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every episode of bacteremia recorded at the Bacteriology Lab-
oratory was registered for the purposes of this study. The
medical records of 373 patients for whom a blood culture
was positive for S. aureus were retrospectively reviewed. Sev-
enteen patients with polymicrobial bacteremia were ex-
cluded. In addition, single positive hemocultures for 57 pa-
tients for whom no further culture yielded the same phage
type were judged as contaminated (see below). Eight of these
patients had a subsequent episode of bacteremia due to an-
other pathogen, 21 patients had postoperative fever with
spontaneous resolution, and in 28 cases the clinical course
did not suggest infection. Records for 18 patients were not
available for the study. The remaining 281 medical charts
were analyzed for data regarding primary and secondary foci,
clinical signs and symptoms, laboratory findings, the treating
physician's opinion in regard to the severity of the infection,
antibiotic treatment, complications, follow-up, phage type,
and in vitro susceptibility of S. aureus. If the presence or
absence of a particular finding was not clearly indicated on a
chart, the case was excluded from analysis in regard to that
finding, a practice that resulted in the use of variable denomi-
nators in the data we present herein.
Contamination. The positivity of a single blood culture
per set (one aerobic and one anaerobic bottle) was consid-
ered indicative of contamination, unless an identical strain
of S. aureus was additionally cultivated from a specimen
from a focus in a patient who had appropriate clinical signs
[13, 14].
Episode. An episode of bacteremia was defined when the
results of the cultures were positive or when results of a fur-
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ther hemoculture were positive later than 1 week after nega-
tive results were obtained [15].
Acquisition. Bacteremia was judged to be community ac-
quired (CA) when the positive culture results were obtained
at or within 48 hours after admission or when there was evi-
dence of S. aureus infection on admission [10, 16-18]. Bac-
teremia was judged to be hospital acquired (HA) when the
positive culture results were obtained >48 hours after hospi-
talization. Episodes of bacteremia secondary to infections of
dialysis access sites were considered to be due to HA organ-
isms.
Underlying conditions. Glucocorticosteroid therapy was
considered a risk factor if a patient had received the daily
equivalent of >25 mg of prednisone for at least 1 week prior
to the time the positive blood culture results were obtained
[19]. Chronic renal failure was defined as a persistent rise in
serum creatinine levels to >180 Amol/L [20]. Diabetes mel-
litus was a risk factor in cases of insulin dependency or
chronic treatment with oral hypoglycemic agents [20]. Pre-
vious hospitalization within 30 days of onset of illness was
viewed as predisposing the patient to septicemia [21]. Other
conditions frequently cited as predisposing factors to infec-
tion (table 1) were established as being either present or ab-
sent in each episode [4, 5, 10, 16, 20-31].
Clinical significance. Criteria for clinical significance
were used as proposed by Michel et al. [17]. These criteria
were the existence of true bacteremia plus at least three of
the following factors: leukocyte count, >10 X 109/L; temper-
ature, >38.5°C; heart rate, >100/min; chills; hypotension
(systolic blood pressure, <90 mm Hg or a fall of >30 mm
Hg); or new oliguria (urine output, <400 mL/24 hours).
Complicated bacteremia. Bacteremia was considered to
be complicated if a focus of infection was absent or nonre-
movable [32, 33].
Primary and secondary bacteremia. Bacteremia occur-
ring in the absence of an apparent portal of entry was classi-
fied as primary. If a portal of entry was identified, bacteremia
was defined as secondary.
Portal ofentry and secondary foci. The initial staphylococ-
cal lesion leading to bacteremia was defined as the portal of
entry. Other foci were considered as sequelae resulting from
seeding of the initial lesion. Primary infection of the respira-
tory and urinary tracts was diagnosed only when symptoms
and signs typically associated with bacterial infections of
those systems were present and coincident with appropriate
results of culture. The presence of Staphylococcus isolates in
urine was considered to be secondary to bacteremia if the
phage type of organisms isolated from urine and blood
matched. An intravascular catheter was considered as the
portal of entry if (1) there was evidence of inflammation at
the catheter insertion site and/or (2) a catheter-tip culture
was positive for S. aureus and (3) there was no evidence of a
source of infection elsewhere [34]. Endocarditis was defined
according to Nolan and Beaty [23] and Bayer et al. [35].
Prognosis. Patients were classified as three groups ac-
cording to prognosis: (1) good prognosis (patients without
underlying disease); (2) poor prognosis (patients with under-
lying surgical or medical disorders of such severity that recov-
ery from their primary disease was unlikely); and (3) inter-
mediate prognosis (patients not qualifying for a good or poor
prognosis) [36].
Outcome. Treatment failure was defined as clinical deteri-
oration or persistence of disease activity sufficient to warrant
a change in the treatment. When data were not available for
at least 1 month after completion of antibiotic therapy, the
patient was rated as improved instead of cured.
Treatment. Treatment was classified as either local (in-
cluding the removal of infectious foci or surgical therapy) or
systemic (including the initial antibiotic therapy, started be-
fore culture results were available, and the antibiotic therapy
used after sensitivity testing). Treatment was rated as appro-
priate or inappropriate according to well-accepted guide-
lines [37].
Statistical analysis. Statistical analysis was performed
with use of programs of the SAS system (SAS Institute, Cary,
NC). The x 2 test was used for proportional values, and the
Student's t-test, for independent populations. A P value of
was considered significant.
Results
During the 7-year period investigated, 2,746 episodes of
bacteremia were diagnosed in the laboratory. The most fre-
quent isolates were Escherichia coli (22.8%), Streptococcus
species (16.2%), and coagulase-negative staphylococcus
(13.2%). S. aureus was isolated in 373 cases (13.6%). All
cases of staphylococcal bacteremia were observed in either
the surgical or the medical wards, with the exception of 14
cases that were observed in departments dealing with the
following specialties: gynecology and obstetrics (4); derma-
tology (5); ear, nose, and throat disorders (2); paraplegic pa-
tients (2); and ophthalmology (1). The majority of patients
with CA bacteremia (85%) were hospitalized in the medical
departments. The proportion of bacteremic episodes caused
by S. aureus remained relatively stable over the study period.
Acquisition. A majority of cases (200 [71%] of 281) were
HA; 80 (28%) were CA, and in one case the mode of acquisi-
tion was not ascertainable. Over the years the rate of CA
cases of bacteremia varied considerably between 14.6%
(1983) and 38.6% (1986).
Age and sex. The median age was 60 years, within a
range of 1-100 years (only one patient was younger than 10
years old). The majority of cases occurred in the sixth (18%),
seventh (22%), or eighth (20%) decade of life. The median
age of patients with CA vs. HA bacteremia was not signifi-
cantly different (67.5 vs. 58 years). CA bacteremia rarely
occurred in individuals younger than 50 years. Of the 281
patients with bacteremia, 164 (58%) were male and 117
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Table 1. Prevalence of underlying conditions with regard to acquisition of bacteremia due to
S. aureus.
Predisposing factor
No. (%) of patients with factor
per type of bacteremia
P valuer
Total
(n = 281*)
CA
(n	 80)
HA
(n = 200)
Intravascular device 160 (57) 0 160 (80) <.00I
Surgical wound 103 (37) 6 (7.5) 96 (48) <.001
Arteriosclerotic heart disease 69 (25) 20 (25) 49 (25) NS
Previous hospitalization 61 (22) 9(11) 51(26) <.005
Implants* 53 (19) 11 (14) 42 (21) NS
Alcohol abuse 51 (19) 7 (9) 44 (23) .035
Malignancy 50 (18) 11 (14) 39 (20) NS
Corticosteroids 49 (17) 5 (6) 44 (22) <.007
Diabetes mellitus 48 (17) 18 (23) 30 (15) NS
Trauma 41 (15) 2 (2) 39 (20) <.00I
Chronic renal failure* 34 (12) I 1 (14) 23 (11.5) NS
Cytostatic and immunosuppressive therapy 29 (10) 4 (5) 25 (12.5) NS
Chronic rheumatic heart disease 23 (8) 10 (12.5) 13 (6.5) NS
Tracheostomy/artificial ventilation 19 (7) 19 (9.5) NS
Cirrhosis of liver 15 (5) 2 (2.5) 13 (6.5) NS
Cardiomyopathy 11 (4) 4 (5) 7 (3.5) NS
Rheumatoid arthritis 8 (3) 5 (6) 3 (1.5) NS
Intravenous drug abuse 4 (1.4) 3 (4) 1 (0.5) NS
Congenital heart disease 1 (0.4) 1	 (1) NS
Other 43 (15) 11 (14) 32 (16) NS
None 13 (5) 9(11) 4 (2) NS
* One patient's bacteremia was classified neither as CA nor as HA. He suffered from S. aureus sepsis after
outpatient surgery.
t The X2 test was applied. NS = not significant (i.e., P > .05).
* Thirty-two (60%) of the implants were not infected.
*Including 15 patients undergoing dialysis.
(42%) were female. CA bacteremia occurred more frequently
in females (33%) than in males (25%).
Underlying conditions. Table 1 shows the underlying
conditions that were present in 268 subjects (95%). They
were found in 98% of patients with HA bacteremia and 87%
of patients with CA bacteremia. Many patients had more
than one underlying condition. There were only four pa-
tients with a history of intravenous drug abuse. No patient
was infected with the human immunodeficiency virus. For
patients with HA bacteremia, predisposing factors more of-
ten were intravenous catheters, surgical wounds, previous
hospitalization, alcohol abuse, therapy with corticosteroids,
and trauma. Of the 200 patients with HA bacteremia, 160
(80%) had an intravascular device; this device was proved
bacteriologically and/or clinically to be the portal of entry
for S. aureus for 38.5% of these patients (table 2).
Clinical signs and symptoms and laboratory findings. At
the time their first positive blood culture results were ob-
tained, 91% of the patients had fever and the general condi-
tion of 85% was impaired. Thirty-eight percent presented
with clouding of consciousness, and one-quarter suffered
from chills. Vomiting, nausea, myalgia, and dyspnea were
reported in 13%-14%. Shock (9%), hemiplegia (6%), stiff
neck (4%), diarrhea (2.5%), headache (1.5%), and seizures
(1%) were less frequent. Only 1% showed no clinical abnor-
malities at the time the hemoculture was performed.
Primary vs. secondary bacteremia. In 219  patients (78%)
an apparent primary site of S. aureus infection was identified.
Among patients with HA bacteremia the detection of a por-
tal of entry (i.e., secondary bacteremia) was more common
than among patients with CA bacteremia (88% vs. 54%; x 2 --
37.355; P < .001). The sites of primary foci are summarized
in table 2.
Complicated vs. uncomplicated bacteremia. Among the
whole study group, 176 patients (63%) had complicated bac-
teremia, as defined by the existence of a nonremovable ini-
tial focus. Significantly fewer patients with CA bacteremia
had a removable focus than did patients with HA bacteremia
(2.5% vs. 51%; )(2 = 51.810; P < .001).
Clinical significance of bacteremia. Overall, 60% of the
cases of bacteremia were clinically significant. In 4% no classi-
fication could be made. Sixty-eight percent of cases of HA
bacteremia but only 46% of cases of CA bacteremia were
clinically significant (x2 = 9.874; P < .002).
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Table 2. Portal of entry for S. aureus.
Site or condition
No. of patients (%) with indicated
type of acquisition of infection
CA
(n = 80)
HA
(n = 200)
Peripheral iv catheter 24 (12)
Central iv catheter 53 (26.5)
Wounds 29 (14.5)
Primary pneumonia 6 (7.5) 21 (10.5)
Urinary catheter 3 (4) 13 (6.5)
Injections I (1) I (0.5)
Implants 4 (5) 7 (3.5)
Skin 6 (7.5) 5 (2.5)
Others* 23 (29) 23 (11.5)
None 37 (46) 24 (12)
* Perforating ulcer of the foot and/or osteomyelitis ( 18), transvenous pace-
maker (5), bronchitis (3), dental abscess (3), arteriovenous shunt infection
(3), urinary tract infection (3), gluteal abscess (2), intraarticular injection
(2), epidural catheter (1), vesical catheter ( 1 ), pleural catheter ( 1 ), acne
conglobata (I), intestinal infection ( 1 ), throat infection (1), and anterior
and posterior nasal tamponade ( I ).
Secondary foci of bacteremia. Metastatic staphylococcal
foci demonstrated by roentgenography, scintigraphy, surgi-
cal drainage, puncture, histology, or autopsy were noted in
75 patients (27%). The foci were in the following sites: joint
(27 patients), kidney (22), CNS (21), myocardium (17), skin
(12), intervertebral disk (11), lung (10), bone (8), spleen (7),
subcutis (3), liver (3), vascular system (3), hematomas (3),
small intestine (2), and the eye, bursa olecrani, pericardium,
pancreas, and thyroid gland (1 each). In most cases (50.7%) a
single metastatic focus was detected. Metastasizing foci were
more common in cases of primary vs. secondary bacteremia
(51% vs. 21%; x2 = 21.471; P < .001). They were also more
frequent in cases of CA bacteremia than in those of HA bac-
teremia (43% vs. 21%; x 2 = 14.036; P < .001). Only 19% of
cases of uncomplicated bacteremia were followed by the de-
velopment of secondary foci, as compared with 32% of cases
of complicated bacteremia (x2 = 4.949, P < .05).
Endocarditis. Endocarditis was diagnosed in 8.2% of all
patients with bacteremia at any time during the course of
hospitalization. In spite of the various types of bacteremia,
only the presence or absence of primary foci correlated with
a significant difference in the incidence of endocarditis (6%
vs. 17%; x2 = 4.9128; P = .0267). Fourteen of the patients
with CA bacteremia but only 6% with HA bacteremia devel-
oped endocarditis (P = .09).
Acute complications. Septic shock was observed in 48 pa-
tients (17.1%); acute respiratory distress syndrome, in 14
(5%); and disseminated intravascular coagulation, in 28
(10%). The latter complication was more common in cases of
CA vs. HA bacteremia (17.5% vs. 7%; x2 = 4.5714; P
= .0325).
Prognosis. The large proportion of patients with a poor
prognosis (57%) points to the importance of the underlying
condition as risk factor for S. aureus bacteremia. Patients
with HA bacteremia had a poor prognosis more frequently
than did patients with CA bacteremia (63.5% vs. 41%; X2 =
9.704; P = .002). Similarly, a good prognosis was more fre-
quent among patients with CA bacteremia (15%) than
among those with HA bacteremia (4%) (x2 = 5.8156; P
= .016).
Therapy. Only 43% of all patients with bacteremia could
be considered cured, and in 14% an improvement in their
condition was noted. Sustained treatment failure or relapse
was observed in 24% and 8% of the patients, respectively. In
11% of cases no clear statement about the efficacy of therapy
could be made, either because antibiotics were withheld
owing to an unfavorable prognosis in regard to underlying
disease or because the patient was transferred to another hos-
pital. A significantly higher percentage of patients with HA
bacteremia were cured than were patients with CA bacter-
emia (47% vs. 31%; x 2 = 4.728; P = .029). Initially over
one-quarter of all patients with bacteremia received inappro-
priate antibiotic treatment. For uncomplicated cases of bac-
teremia, 17% of the initial treatments were inappropriate, as
compared with 32% for complicated cases of bacteremia (x 2
= 6.834; P = .009). Sixty-one patients with bacteremia un-
derwent surgical removal of a primary or secondary focus.
Surgery was more frequently performed in patients with
complicated bacteremia than in those with uncomplicated
bacteremia (29% vs. 9.5%; X. 2 = 14.742; P < .001).
The median duration of antimicrobial therapy for 257 bac-
teremic patients was 15 days (range, 0-157 days). Seventy
patients with CA bacteremia received antibiotics for a me-
dian of 22 days (mean, 30.7 days), and 187 patients with
nosocomial infection were treated for a median of 12 days
(mean, 16.2 days). A total of 104 patients with uncompli-
cated bacteremia were treated with use of an intravenous
catheter for a median of 9.5 days (mean, 11.3 days; range,
0-60 days); two patients were cured by catheter removal
without use of antibiotics.
At the time of the first blood culture positive for S. aureus,
the treating physician judged 48 (19%) of 247 patients to be
irrelevantly infected or the blood culture to be contami-
nated. For these patients no therapy was started, or an inap-
propriate initial treatment was not changed according to the
susceptibility pattern of the isolate. After the introduction of
an infectious disease service at the hospital in 1982, the num-
ber of misinterpreted blood cultures dropped from 12 to 4.8
per year.
Mortality rate. The overall mortality rate among patients
with S. aureus bacteremia was 33.6%. In 20% of cases, death
was directly related to S. aureus, and in 28%, to the underly-
ing illness. In 52% of the patients, the cause was unclear or
not due to the S. aureus infection alone. A comparison of the
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death rates associated with differently defined bacteremia
demonstrated that uncomplicated bacteremia was associated
with a lower mortality rate than was complicated bacteremia
(24% vs. 40%; )( 2 = 6.829, P < .01). Similarly, secondary
bacteremia was also associated with a lower mortality rate
(30% vs. 45%, )(2 = 4.183, P = .05). There was no signifi-
cance in the differences between CA and HA bacteremia and
between clinically significant and insignificant bacteremia in
regard to mortality. The mortality rate was higher among
patients with endocarditis (65%; n = 23) as compared with
patients with secondary foci of infection who did not have
endocarditis (49%, n = 57) (x2 = 4.5859; P = .03). The
mortality rate among patients without any metastatic infec-
tions (n = 201) was 25%, a significantly lower rate than the
49% found among patients with secondary foci (x2 =
30.7272; P < .001).
Sensitivity pattern. During the investigated period, only
one methicillin-resistant strain-which was also resistant to
erythromycin, doxycycline, chloramphenicol, and trimetho-
prim-sulfamethoxazole-was isolated.
Discussion
The aim of our study was to evaluate different previously
published clinical case definitions of S. aureus bacteremia
[17, 23, 32-36]. S. aureus remains a significant pathogen,
causing 13.6% of all cases of bacteremia at our hospital. This
finding is consistent with the results of other series showing
rates of 7.5%-25% (mostly between 10% and 15%) [1, 7, 9,
10, 12, 13, 16-18, 20, 36, 38-42]. In the literature, varied
meanings of the same terms regarding the different clinical
case definitions can be found. Secondary bacteremia, most
often defined as bacteremia with an identified portal of
entry, has been described also as bacteremia developing dur-
ing the course of another fatal disease [8]. Complicated bac-
teremia has been described as bacteremia complicated by
secondary foci and other clinical findings [34] as well as bac-
teremia with an undefined or nonremovable focus [32, 33].
Furthermore, cases of HA bacteremia have been defined dif-
ferently with use of various endpoints (48 hours [10, 16-18,
34, 43], 72 hours [35], 96 hours [9, 23, 44], or even 1 week
[22] after admission to the hospital) for distinguishing them
from cases of CA bacteremia. These variations impede a reli-
able comparison.
In our series the comparison of various clinical case defini-
tions thought to be predictive of the outcome [9, 10, 15, 21,
23, 28, 45-48] shows that a statistically significant better
outcome with regard to mortality rate, occurrence of second-
ary foci, and endocarditis is achieved only in cases of second-
ary bacteremia. The higher incidence of endocarditis and sec-
ondary foci in cases of primary bacteremia, which was also
observed by others [5, 23, 24], may be due to delayed treat-
ment with effective antibiotics in the absence of a primary
focus.
HA bacteremia was less often followed by secondary foci
and endocarditis but was associated with a mortality rate simi-
lar to that associated with CA bacteremia, a finding which
was also observed in a newer prospective study [49]. The
more benign course of HA bacteremia is well known from
the literature [9, 48, 50, 51]. However, the mortality rate
remains high, and additional factors such as underlying con-
ditions [24, 36, 43], the age of the patients [10, 21, 23, 45],
and the nature of the primary infection appear to influence
the outcome. Cases of uncomplicated bacteremia were signif-
icantly less often followed by secondary foci and were asso-
ciated with a lower mortality rate than were complicated
cases, but the two did not differ in terms of the associated
incidence rate of endocarditis. A low risk of subsequent sec-
ondary foci after an episode of uncomplicated bacteremia
was also reported in two prospective studies [52, 53],
whereas the low incidence of endocarditis in these and other
investigations [9, 41] contrasted with the results of our study.
Watanakunakorn and Baird [46] mentioned in their study
the significant risk of developing endocarditis after an epi-
sode of uncomplicated bacteremia, whereas in a recent pub-
lication [40] the risk was called "small but definite."
In our series, the mortality rate was highest among patients
with no or nonremovable foci, a finding which may be ex-
plained by the delay in instituting effective treatment. The
earlier awareness of the possibility of bacteremia in cases
with obvious local staphylococcal lesions and, consequently,
the institution of significantly more appropriate and earlier
treatment may have prevented many sequelae. Michel et al.
[17] showed a 4.4-fold higher mortality rate among patients
with "clinically significant bacteremia," as defined in their
Methods section. In contrast, in our series this classification
was not discriminative in terms of the fatality rate. This may
be because of the fact that before the introduction of an in-
fectious disease service, a considerable proportion of patients
with subtle symptoms received no or inadequate therapy in
our hospital.
In conclusion, S. aureus bacteremia remains a major prob-
lem and is associated with a high rate of mortality. The pres-
ence of a source of bacteremia was the only factor predictive
of the outcome. Patients for whom the source of bacteremia
was defined had a better prognosis with regard to mortality
rate, incidence of endocarditis, and secondary foci. Our data
suggest that an improvement of the prognosis could be
achieved by more competent interpretation of positive blood
cultures yielding S. aureus and by earlier initiation of antista-
phylococcal therapy.
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